Financial PositionThe stock continues to trade near its total liquidity, implying upside from ABCL's royalty portfolio and internal pipeline.
Research And DevelopmentAbCellera is focusing on its two leading internal R&D programs, ABCL635 in the metabolic and endocrinology medical area and ABCL575, targeting immunology and inflammation.
Strategic PartnershipsAbCellera succeeded in signing two new partnerships in 2024, with Biogen and venture firms Viking and ArrowMark, and expanding two legacy programs.